Physician Referrals Mounting, and Costs Too?

The percentage and absolute number of ambulatory physician office visits resulting in referrals to other physicians has grown substantially in the United States, according to researchers in the Department of Health Care Policy at Harvard Medical School.

The percentage and absolute number of ambulatory physician office visits resulting in referrals to other physicians has grown substantially in the United States, according to researchers in the Department of Health Care Policy at Harvard Medical School. Barnett and associates1 analyzed nationally representative cross-sections of ambulatory patient visits in the United States. The main outcome measures were survey-weighted estimates of the total number and percentage of visits resulting in a referral to another physician across several patient and physician characteristics.

From 1999 to 2009, the probability that an ambulatory visit to a physician would result in a referral to another physician jumped from 4.8% to 9.3%, a 94% increase. The absolute number of visits resulting in a physician referral increased 159% nationally, from 41 million to 105 million. Changes in referral rates varied according to the principal symptoms accounting for patients’ visits; significant increases were noted for visits to primary care physicians from patients with cardiovascular, GI, orthopedic, dermatologic, and ear/nose/throat symptoms. The authors noted that more research is needed to understand the contribution of rising referral rates to costs of care.

References:

References

1. Barnett ML, Song Z, Landon BE. Trends in physician referrals in the United States, 1999-2009. Arch Intern Med. 2012;172:163-170.

Related Videos
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
Ladan Zand, MD: Obinutuzumab Promising Option for Refractory, Primary FSGS
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
© 2024 MJH Life Sciences

All rights reserved.